David Langleben

21.6k total citations · 9 hit papers
163 papers, 14.3k citations indexed

About

David Langleben is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Physiology. According to data from OpenAlex, David Langleben has authored 163 papers receiving a total of 14.3k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Pulmonary and Respiratory Medicine, 88 papers in Cardiology and Cardiovascular Medicine and 18 papers in Physiology. Recurrent topics in David Langleben's work include Pulmonary Hypertension Research and Treatments (135 papers), Cardiovascular Issues in Pregnancy (45 papers) and Cardiovascular Function and Risk Factors (26 papers). David Langleben is often cited by papers focused on Pulmonary Hypertension Research and Treatments (135 papers), Cardiovascular Issues in Pregnancy (45 papers) and Cardiovascular Function and Risk Factors (26 papers). David Langleben collaborates with scholars based in Canada, United States and France. David Langleben's co-authors include Robert D. Levy, Lewis J. Rubin, Nazzareno Galiè, David B. Badesch, Gérald Simonneau, Duncan J. Stewart, Robyn J. Barst, Maurice Beghetti, Stuart Rich and Zhi‐Cheng Jing and has published in prestigious journals such as New England Journal of Medicine, Circulation and Annals of Internal Medicine.

In The Last Decade

David Langleben

156 papers receiving 13.8k citations

Hit Papers

A Comparison of Continuous Intravenous Epoprostenol (Pros... 1991 2026 2002 2014 1996 2009 1993 2004 2013 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
    1996 2.0k citations Robyn J. Barst, Lewis J. Rubin et al. profile →
  2. Updated Clinical Classification of Pulmonary Hypertension
    2009 1.5k citations Gérald Simonneau, Ivan M. Robbins et al. profile →
  3. Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension
    1993 1.4k citations David Langleben et al. profile →
  4. Clinical classification of pulmonary hypertension
    2004 1.3k citations Gérald Simonneau, Nazzareno Galiè et al. profile →
  5. Definitions and Diagnosis of Pulmonary Hypertension
    2013 1.3k citations Marius M. Hoeper, David Langleben et al. profile →
  6. Riociguat for the Treatment of Pulmonary Arterial Hypertension
    2013 944 citations Hossein Ardeschir Ghofrani, Nazzareno Galiè et al. profile →
  7. Increased Plasma Endothelin-1 in Pulmonary Hypertension: Marker or Mediator of Disease?
    1991 771 citations David Langleben et al. profile →
  8. Sitaxsentan Therapy for Pulmonary Arterial Hypertension
    2003 540 citations Robyn J. Barst, David Langleben et al. American Journal of Respiratory and Critical Care Medicine profile →
  9. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update
    2018 349 citations Anton Vonk Noordegraaf, Paul M. Hassoun et al. European Respiratory Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Langleben Canada 41 12.3k 8.2k 2.2k 2.1k 1.8k 163 14.3k
David Montani France 67 13.8k 1.1× 6.7k 0.8× 2.6k 1.2× 1.3k 0.6× 2.1k 1.2× 397 16.6k
Ivan M. Robbins United States 42 10.9k 0.9× 7.0k 0.9× 2.2k 1.0× 806 0.4× 1.4k 0.8× 106 12.2k
Richard N. Channick United States 51 13.0k 1.1× 9.1k 1.1× 2.9k 1.3× 974 0.5× 1.5k 0.8× 222 14.7k
Xavier Jaïs France 62 11.4k 0.9× 6.8k 0.8× 2.6k 1.2× 707 0.3× 1.7k 1.0× 261 12.7k
Ronald J. Oudiz United States 48 10.3k 0.8× 7.7k 0.9× 1.8k 0.8× 683 0.3× 1.1k 0.6× 127 11.7k
Vallerie V. McLaughlin United States 64 19.4k 1.6× 13.5k 1.6× 3.7k 1.7× 1.3k 0.6× 2.1k 1.2× 273 21.5k
Stuart Rich United States 68 19.2k 1.6× 14.3k 1.7× 3.7k 1.7× 1.5k 0.7× 3.1k 1.7× 183 23.1k
Zhi‐Cheng Jing China 39 8.6k 0.7× 5.8k 0.7× 1.6k 0.7× 696 0.3× 1.1k 0.6× 221 10.6k
Raymond L. Benza United States 48 8.8k 0.7× 7.1k 0.9× 1.8k 0.9× 462 0.2× 2.3k 1.3× 316 12.2k
Ekkehard Grünig Germany 50 9.4k 0.8× 6.7k 0.8× 1.3k 0.6× 623 0.3× 789 0.4× 253 11.5k

Countries citing papers authored by David Langleben

Since Specialization
Citations

This map shows the geographic impact of David Langleben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Langleben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Langleben more than expected).

Fields of papers citing papers by David Langleben

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Langleben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Langleben. The network helps show where David Langleben may publish in the future.

Co-authorship network of co-authors of David Langleben

This figure shows the co-authorship network connecting the top 25 collaborators of David Langleben. A scholar is included among the top collaborators of David Langleben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Langleben. David Langleben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Vassiliou, Alice G., Chrysi Keskinidou, Nikolaos Athanasiou, et al.. (2024). Transpulmonary Plasma Endothelin-1 Arterial:Venous Ratio Differentiates Survivors from Non-Survivors in Critically Ill Patients with COVID-19-Induced Acute Respiratory Distress Syndrome. International Journal of Molecular Sciences. 25(19). 10640–10640.
3.
Benza, Raymond L., Gérald Simonneau, Hossein Ardeschir Ghofrani, et al.. (2024). Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study. The Journal of Heart and Lung Transplantation. 43(10). 1756–1760. 1 indexed citations
4.
Preston, Ioana R., Luke Howard, David Langleben, et al.. (2024). Management of pulmonary hypertension in special conditions. European Respiratory Journal. 64(4). 2401180–2401180. 6 indexed citations
5.
Keskinidou, Chrysi, Ioanna Dimopoulou, Αnastasia Kotanidou, et al.. (2024). Effects of Modulating BMP9, BMPR2, and AQP1 on BMP Signaling in Human Pulmonary Microvascular Endothelial Cells. International Journal of Molecular Sciences. 25(15). 8043–8043. 1 indexed citations
6.
Benza, Raymond L., David Langleben, Anna R. Hemnes, et al.. (2022). Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Review. 31(166). 220061–220061. 10 indexed citations
7.
Vassilatou, Evangeline, et al.. (2022). The Role of Thyroid Disorders, Obesity, Diabetes Mellitus and Estrogen Exposure as Potential Modifiers for Pulmonary Hypertension. Journal of Clinical Medicine. 11(4). 921–921. 6 indexed citations
8.
9.
Langleben, David, Stylianos E. Orfanos, Robert Schlesinger, et al.. (2019). Pulmonary capillary surface area in supine exercising humans: demonstration of vascular recruitment. American Journal of Physiology-Lung Cellular and Molecular Physiology. 317(3). L361–L368. 13 indexed citations
10.
Hoeper, Marius M., et al.. (2016). The RESPITE Study: Riociguat In Patients With Pah And An Inadequate Response To Phosphodiesterase 5 Inhibitors. 2 indexed citations
11.
Benza, Raymond L., Mardi Gomberg‐Maitland, Teresa DeMarco, et al.. (2015). Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 192(11). 1345–1354. 72 indexed citations
12.
Rubin, Lewis J., Nazzareno Galiè, Friedrich Grimminger, et al.. (2014). Late-breaking abstract: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension. European Respiratory Journal. 44(Suppl 58). P1803–P1803. 10 indexed citations
13.
Galiè, Nazzareno, Friedrich Grimminger, Ekkehard Grünig, et al.. (2014). Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension. CHEST Journal. 145(3). 513A–513A. 3 indexed citations
14.
15.
Grünig, Ekkehard, Nazzareno Galiè, Marc Humbert, et al.. (2013). Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study. European Respiratory Journal. 42(Suppl 57). 1783–1783. 1 indexed citations
16.
Galiè, Nazzareno, Friedrich Grimminger, Ekkehard Grünig, et al.. (2013). Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT-1 study. European Respiratory Journal. 42(Suppl 57). 1784–1784. 5 indexed citations
17.
Ghofrani, Hossein Ardeschir, Nazzareno Galiè, Friedrich Grimminger, et al.. (2013). Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH). European Respiratory Journal. 42(Suppl 57). P3419–P3419. 1 indexed citations
18.
Delcroix, Marion, Gérald Simonneau, Emmanuel Bergot, et al.. (2013). Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension. European Respiratory Journal. 42(Suppl 57). P4080–P4080. 1 indexed citations
19.
Therrien, Judith, William G. Newman, Kathy Siminovitch, et al.. (2006). Eisenmenger syndrome and atrial septal defect: Nature or nurture?. Canadian Journal of Cardiology. 22(13). 1133–1136. 20 indexed citations
20.
Barst, Robyn J., David Langleben, Adaani Frost, et al.. (2003). Sitaxsentan Therapy for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 169(4). 441–447. 540 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Montani Breakdown of academic impact, for papers by Ivan M. Robbins Breakdown of academic impact, for papers by Richard N. Channick Breakdown of academic impact, for papers by Xavier Jaïs Breakdown of academic impact, for papers by Ronald J. Oudiz Breakdown of academic impact, for papers by Vallerie V. McLaughlin Breakdown of academic impact, for papers by Stuart Rich Breakdown of academic impact, for papers by Zhi‐Cheng Jing Breakdown of academic impact, for papers by Raymond L. Benza Breakdown of academic impact, for papers by Ekkehard Grünig
Rankless by CCL
2026